Hypothesis\nAging reduces colonic NAD+ levels, which diminishes tetrahydrobiopterin (BH4) recycling and thereby limits TPH1 activity in enterochromaffin (EC) cells, causing a decline in gut‑derived serotonin that contributes to age‑related motility dysfunction.\n\n## Mechanistic Rationale\n- NAD+ is a cofactor for the salvage pathway that regenerates BH4 from dihydrobiopterin via enzymes such as GTP cyclohydrolase I (GCH1) and sepiapterin reductase; reduced NAD+ lowers NADPH availability, impairing BH4 regeneration.[1]\n- BH4 is an essential cofactor for TPH1; insufficient BH4 shifts TPH1 toward uncoupled activity, producing superoxide instead of serotonin.[2]\n- NAD+‑dependent sirtuins (SIRT1/SIRT2) deacetylate TPH1, enhancing its catalytic efficiency; NAD+ loss leads to hyperacetylation and reduced enzyme activity.[3]\n- EC‑cell mechanosensing via Piezo2 remains intact, but the biochemical capacity to convert tryptophan to 5‑HT is compromised.\n\n## Predictions & Experimental Design\n1. EC‑cell‑specific NAD+ boost – Generate mice with EC‑cell‑targeted expression of NAMPT (using Tph1‑Cre) or administer EC‑cell‑directed NMN nanoparticles. Predict: restored TPH1 activity, normal colonic serotonin levels, and improved colonic transit in aged mice despite unchanged microbiota composition.\n2. NAD+ depletion in young mice – Treat young mice with EC‑cell‑specific NAMPT shRNA or systemic FK866 (NAMPT inhibitor). Predict: rapid decline in EC‑cell serotonin production and motility resembling aged phenotype.\n3. Microbiota independence – Perform the above experiments in germ‑free or antibiotic‑treated animals. Predict: NAD+ manipulation effects on EC‑cell serotonin persist, indicating a microbiota‑independent mechanism.\n4. Readouts – Measure colonic TPH1 enzyme activity (conversion of tryptophan to 5‑HT in isolated EC cells), luminal serotonin via HPLC, BH4/biopterin ratios, colonic transit time (carmine red assay), and Piezo2‑mediated release (mechanical stretch ex vivo).\n\n## Potential Outcomes & Interpretation\n- If EC‑cell NAD+ supplementation rescues serotonin and motility without altering microbiota, the hypothesis is supported, positioning NAD+‑BH4‑TPH1 axis as a primary driver of age‑related EC‑cell decline.\n- If serotonin remains low despite NAD+ restoration, alternative mechanisms (e.g., Piezo2 downregulation, EC‑cell loss) must be investigated.\n- If young mice show premature EC‑cell dysfunction after NAD+ depletion, it establishes NAD+ as a sufficient early regulator of EC‑cell function, reinforcing the causal link.\n\nThis framework directly tests whether the age‑related NAD+ decline impairs EC‑cell serotonin synthesis via BH4 dysregulation, offering a tractable target for interventions aimed at preserving gastrointestinal motility in older populations.
